方法：选择入住我院PDR患者112例125眼，随机分为试验组与对照组各56例。试验组56例61眼采取玻璃体腔内注射雷珠单抗0.5mg的药物治疗，之后行玻璃体切割术； 对照组56例64眼患者单行玻璃体切割术。分析2组患者在术中、术后若干临床指标的差异。

结果：试验组平均手术用时、术中电凝止血频率及医源裂孔发生率均低于对照组，分别为95.00±13.00min vs 133.00±14.5min，11%vs 34%，5%vs 20%(均P<0.05)。试验组术后1mo内前房和玻璃体腔积血率均较对照组降低，分别为7% vs 23%，5% vs 12%(均P<0.05)。术后试验组患者视力较对照组更好，0.375±0.210 vs 0.261±0.170(P<0.05)。

结论：PDR患者在玻璃体切割术前行玻璃体腔内注射雷珠单抗可有效降低手术时间，减少术中出血量，降低医源性裂孔发生率，减少术中术后并发症，术后视力恢复较好。

METHODS: In this study, 112 cases(125 eyes)with PDR were selected and randomly divided into experimental group and control group(n=56). Fifty-six cases(61 eyes)in experimental group were injected by drug therapy of 0.5mg ranibizumab and received vitrectomy; In control group, 56 cases(64 eyes)were received single vitrectomy. The intraoperative and postoperative differences of clinical indicators were analyzed in two groups.

RESULTS: The average operation time, intraoperative electric coagulation hemostasis rate and iatrogenic hiatal incidence of the experimental group were lower than that of the control group:(95.00±13.00)min vs(133.00±14.5)min, 11% vs 34%, 5% vs 20%, respectively(P<0.05). The anterior chamber and vitreous body cavity hemorrhage rate within postoperative 1mo in the experimental group were lower than that of the control group: 7% vs 23%, 5% vs 12%, respectively(P<0.05). The postoperative visual acuity of experimental group was better than that of the control group: 0.375±0.210 vs 0.261±0.170, respectively(P<0.05).

CONCLUSION: Patients with PDR injected with ranibizumab in vitreous cavity before vitrectomy can effectively reduce the operation time, less intraoperative blood loss, the incidence of iatrogenic hiatus, and intraoperative and postoperative complications. The postoperative visual acuity was better than before.